THE RUSSIAN COMPANY TAKEDA ANNOUNCED REGISTRATION IN RUSSIA OF A NEW READINGS OF ADCETRIS® PREPARATION (BRENTUKSIMAB VEDOTIN)
Takeda Russia announced the launch of two new indications of Adsetris® on the Russian market: 1) the treatment of previously untreated patients with classical CD30 + Hodgkin’s lymphoma stage IV in combination with doxorubicin, vinblastine and dacarbazine; 2) the treatment of patients with CD30 + T-cell lymphoma of the skin after at least one line…